Henlius upholds the talent philosophy of "attracting people with visions, engaging people with rewards, cultivating people with challenges and assessing people with performance" and makes great efforts in attracting, empowering, retaining people and putting right people to right place.

复宏汉霖已成功上市四款自主开发的单抗生物类似药，包括首个国产生物类似药汉利康®（利妥昔单抗）、自主研发的中美欧三地获批单抗生物类似药汉曲优®（曲妥珠单抗）、汉达远®（阿达木单抗）以及汉贝泰®（贝伐珠单抗），引领了中国生物医药行业的快速发展。

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases.

2024年4月26日 · The success of the FDA PLI, as well as the previous GMP certifications from China and EU regulatory agencies, make Henlius a biopharmaceutical company GMP-certificated by China, the EU and U.S. for the manufacturing of self-developed antibody drugs.

2024年10月21日 · Recently, Henlius announced that the clinical trial notification (CTN) for phase 3 international multicenter clinical study of Henlius’ novel anti-HER2 mAb, HLX22, in combination with trastuzumab and chemotherapy for the first-line treatment of HER2-positive advanced gastric cancer has been permitted by Japan’s Pharmaceuticals and Medical ...

2023年9月22日 · Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone.

2024年1月2日 · Shanghai, China, 4th December 2024 – Shanghai Henlius Biotech, Inc. (2696.HK) announced that the new drug application (NDA) has been accepted by the National Medical Products Administration (NMPA) for its self-developed pertuzumab biosimilar HLX11, in combination with trastuzumab and chemotherapy, as adjuvant treatment of patients with HER2 ...

1H22: The Pivotal 6 Months of Henlius’ Evolution from Biotech to Biopharma Sustained operations during Covid outbreaks and lockdowns Doubled production capacity, breaking through the bottleneck Received NMPA approval for the first innovative biological drug, Serplulimab

2024年12月17日 · Recently, Henlius has been announced as the newest member company of the Biosimilars Forum, a coalition that advances biosimilars in United States with the intent of expanding access and availability of biological medicines and improving health care.

Shanghai, China, Dec 13 th, 2023 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first subject was dosed for a phase 1 clinical trial of the company's independently developed ipilimumab biosimilar HLX13 (recombinant anti-CTLA-4 fully human monoclonal antibody injection) in China.